CEL SCI CORP
CVM · XNYSCIK 725363fmd_0AEXTYXXJ5NFPM5P2Q3T87QDSWManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Oct 01, 2008 to Jun 30, 2026, 66 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | – | – | – | – |
| Net interest income | (2) | – | – | (2) | (1) | (1) | (1) | – | (1) | (1) |
| Realized investment gains (losses) | – | – | – | – | – | 0 | 0 | 0 | – | – |
| Research and development | 17 | 16 | 11 | 13 | 18 | 23 | 25 | 22 | 18 | 16 |
| Total operating expenses | 24 | 21 | 17 | 21 | 30 | 36 | 36 | 31 | 26 | 25 |
| Operating income | (24) | (21) | (17) | (20) | (29) | (36) | (36) | (31) | (26) | (25) |
| Interest expense | – | – | – | – | 1 | – | 1 | 1 | 1 | 1 |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (2) | – | – | – | 0 | (0) | 0 | (0) | 0 | 0 |
| Income before taxes | – | – | – | (22) | (30) | – | – | – | – | – |
| Net income from continuing operations | (24) | – | – | – | – | – | – | – | – | – |
| Net income | (12) | (14) | (32) | (22) | (30) | (36) | (37) | (32) | (27) | (25) |
| Net income to common shareholders | (12) | (14) | (32) | (22) | (30) | (37) | (38) | (32) | (28) | (25) |